Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/13/2017 01/17/2017 01/18/2017 01/19/2017 01/20/2017 Date
1.56(c) 1.5469(c) 1.47(c) 1.4(c) 1.15(c) Last
93 299 211 203 377 969 777 121 8 865 459 Volume
-1.27% -0.84% -4.97% -4.76% -17.86% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -30,9 M
Net income 2017 -28,4 M
Finance 2017 39 976 M
Yield 2017 -
Sales 2018 1,05 M
EBIT 2018 -36,2 M
Net income 2018 -34,0 M
Debt 2018 194 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 0
EV / Sales2018 294x
Capitalization 113 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Surperformance© ratings of Pluristem Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on PLURISTEM THERAPEUTICS INC
01/20 PLURISTEM THERAPEUTICS INC : Entry into a Material Definitive Agreement, Financi..
01/20 FRIDAY SECTOR LAGGARDS : Biotechnology, Aerospace & Defense Stocks
01/20 PLURISTEM THERAPEUTICS : Receives Clearance from Germany to Initiate Its Multina..
01/20 PLURISTEM THERAPEUTICS : Announces Bought Deal Offering
01/20 Pluristem Increases Previously Announced Bought Deal Offering of Common Stock..
01/19 PLURISTEM THERAPEUTICS : Announces Bought Deal Offering
01/17 PLURISTEM THERAPEUTICS INC : Other Events (form 8-K)
01/17 PLURISTEM THERAPEUTICS : Receives Clearance from Germany to Initiate its Multina..
01/17 Pluristem Receives Clearance from Germany to Initiate its Multinational Phase..
01/12 PLURISTEM THERAPEUTICS : Phase III Study of PLX-PAD Cells for the Treatment of C..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/20 Midday Gainers / Losers
01/20 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
01/20 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
01/20 Pluristem increases underwriting deal with Wainwright to $15M; shares down 17..
01/17 Pluristem on go in Germany to start late-stage study of PLX-PAD cells to trea..
Advertisement
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 3,25 $
Spread / Average Target 132%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Zami Aberman Chairman & Chief Executive Officer
Yaky Yanay President, COO, CFO, Secretary & Director
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Mark S. Germain Director
Nachum Rosman Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS..-19.58%113
INCYTE CORPORATION17.21%22 141
QUINTILES IMS HOLDINGS..0.07%18 727
CELLTRION, INC.--.--%10 532
LONZA GROUP AG4.14%9 648
ALKERMES PLC0.72%8 523
More Results